Search research articles
Contact Us
Filters
Showing results (531-540 of 993) with videos related to
Page
of 100
Sort By:
Journal of Clinical Pathology
|
February 24, 2021
Comparison between 1973 and 2004/2016 WHO grading systems in patients with Ta urothelial carcinoma of urinary bladder
Claudia Collà Ruvolo, Christoph Würnschimmel, Mike Wenzel, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association
|
March 16, 2020
Adherence to guideline recommendations for multimodality treatment of patients with pT2-3 M0 non-urothelial carcinoma of the urinary bladder: Temporal trends and survival outcomes
Francesco A Mistretta, Cristina Negrean-Dzyuba, Carlotta Palumbo, et al.
The Journal of Urology
|
March 8, 2021
Racial/Ethnic Disparities in Tumor Characteristics and Treatments in Favorable and Unfavorable Intermediate Risk Prostate Cancer
Mike Wenzel, Luigi Nocera, Claudia Collà Ruvolo, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 7, 2024
Effect of concomitant medications on treatment response and survival in non-metastatic castrate resistant prostate cancer: Exploratory analysis of the SPARTAN trial
Soumyajit Roy, Fred Saad, Yilun Sun, et al.
Surgical Oncology
|
January 11, 2021
Metabolic syndrome predicts worse perioperative outcomes in patients treated with radical prostatectomy for non-metastatic prostate cancer
Stefano Luzzago, Carlotta Palumbo, Giuseppe Rosiello, et al.
European Urology
|
September 6, 2024
Association of Declining Prostate-specific Antigen Levels with Clinical Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Receiving [<sup>177</sup>Lu]Lu-PSMA-617 in the Phase 3 VISION Trial
Andrew J Armstrong, Oliver Sartor, Johann de Bono, et al.
The French Journal of Urology
|
May 24, 2025
Multicentric evaluation of recurrence's management after brachytherapy for localized prostate cancer
Yoan Benchimol, Daniel Taussky, Nicolas Thiounn, et al.
Prostate Cancer and Prostatic Diseases
|
June 20, 2026
Efficacy and safety of darolutamide plus androgen-deprivation therapy in Black patients with metastatic hormone-sensitive prostate cancer from the phase 3 ARANOTE trial
Quoc-Dien Trinh, Daniel J George, Neal Shore, et al.
The Prostate
|
November 11, 2024
pSTAT3 Expression is Increased in Advanced Prostate Cancer in Post-Initiation of Androgen Deprivation Therapy
Piotr Bialas, Tamae Kobayashi, Rebecka Hellsten, et al.
The Prostate
|
July 27, 2021
Assessment of the optimal number of positive biopsy cores to discriminate between cancer-specific mortality in high-risk versus very high-risk prostate cancer patients
Mike Wenzel, Christoph Würnschimmel, Francesco Chierigo, et al.
Page
of 100
Search research articles
Search
Showing results (531-540 of 993) with videos related to
Sort By:
Page
of 100
Journal of Clinical Pathology
|
February 24, 2021
Comparison between 1973 and 2004/2016 WHO grading systems in patients with Ta urothelial carcinoma of urinary bladder
Claudia Collà Ruvolo, Christoph Würnschimmel, Mike Wenzel, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association
|
March 16, 2020
Adherence to guideline recommendations for multimodality treatment of patients with pT2-3 M0 non-urothelial carcinoma of the urinary bladder: Temporal trends and survival outcomes
Francesco A Mistretta, Cristina Negrean-Dzyuba, Carlotta Palumbo, et al.
The Journal of Urology
|
March 8, 2021
Racial/Ethnic Disparities in Tumor Characteristics and Treatments in Favorable and Unfavorable Intermediate Risk Prostate Cancer
Mike Wenzel, Luigi Nocera, Claudia Collà Ruvolo, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 7, 2024
Effect of concomitant medications on treatment response and survival in non-metastatic castrate resistant prostate cancer: Exploratory analysis of the SPARTAN trial
Soumyajit Roy, Fred Saad, Yilun Sun, et al.
Surgical Oncology
|
January 11, 2021
Metabolic syndrome predicts worse perioperative outcomes in patients treated with radical prostatectomy for non-metastatic prostate cancer
Stefano Luzzago, Carlotta Palumbo, Giuseppe Rosiello, et al.
European Urology
|
September 6, 2024
Association of Declining Prostate-specific Antigen Levels with Clinical Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Receiving [<sup>177</sup>Lu]Lu-PSMA-617 in the Phase 3 VISION Trial
Andrew J Armstrong, Oliver Sartor, Johann de Bono, et al.
The French Journal of Urology
|
May 24, 2025
Multicentric evaluation of recurrence's management after brachytherapy for localized prostate cancer
Yoan Benchimol, Daniel Taussky, Nicolas Thiounn, et al.
Prostate Cancer and Prostatic Diseases
|
June 20, 2026
Efficacy and safety of darolutamide plus androgen-deprivation therapy in Black patients with metastatic hormone-sensitive prostate cancer from the phase 3 ARANOTE trial
Quoc-Dien Trinh, Daniel J George, Neal Shore, et al.
The Prostate
|
November 11, 2024
pSTAT3 Expression is Increased in Advanced Prostate Cancer in Post-Initiation of Androgen Deprivation Therapy
Piotr Bialas, Tamae Kobayashi, Rebecka Hellsten, et al.
The Prostate
|
July 27, 2021
Assessment of the optimal number of positive biopsy cores to discriminate between cancer-specific mortality in high-risk versus very high-risk prostate cancer patients
Mike Wenzel, Christoph Würnschimmel, Francesco Chierigo, et al.
Page
of 100